David Propper

5.4k citations
78 papers · 3.2k · 1 hit paper · h-index 24

Impact in

    • Venous Thromboembolism Diagnosis and Management
  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Colorectal Cancer Treatments and Studies
    • Pancreatic and Hepatic Oncology Research
    • Cancer Cells and Metastasis

Papers in

    • Pancreatic and Hepatic Oncology Research 15
    • Colorectal Cancer Treatments and Studies 7
    • Cancer Treatment and Pharmacology 5

David Propper

74 papers receiving 3.1k citations

David Propper's Hit Papers

Harnessing cytokines and chemokines for cancer therapy 2022 · 710 citations
7100+1+2Years since publication200400600

Peers

David Propper
Comparison fields: 5 of 122
  • Internal Medicine 193
  • Oncology 1.2k
  • Cancer Research 473
  • Immunology 595
  • Hematology 230
Replace Wim H.J. Kruit with:
Wim H.J. Kruit Netherlands
F. William Orr Canada
Canio J. Refino United States
Adnan Munkarah United States
Michael Scully United Kingdom
Joseph R. Slupsky United Kingdom
Milena Gasco Italy
Takesada Mori Japan
Nobuhisa Ishikawa Japan
Zan Shen China
David Propper relative to Wim H.J. Kruit Netherlands Wim H.J. Kruit's profile →
Citations per field
00.5×5.1×
Wim H.J. Kruit · 1×
Citations per year

Countries citing papers authored by David Propper

Since Specialization
Citations

This map shows the geographic impact of David Propper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Propper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Propper more than expected).

Fields of papers citing papers by David Propper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Propper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Propper. The network helps show where David Propper may publish in the future.

Co-authors

The 25 scholars most cited alongside David Propper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Propper Line = papers co-authored together David Propper links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 78 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Harnessing cytokines and chemokines for cancer therapy
Hit paper breakdown →
2022710
2 2011236
3 2013192
4 2001191
5 2011177
6 2008140
7 2018122
8 2018115
9
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
2001106
10 1999103
11 201898
12
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
200392
13 200474
14 200955
15
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
200053
16 201750
17
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects.
199947
18 200346
19 200341
20
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.
199941

About David Propper

David Propper is a scholar working on Oncology, Molecular Biology, Cancer Research, Hematology and Immunology, having authored 78 papers that have together received 3.2k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (15 papers), Cancer, Hypoxia, and Metabolism (8 papers), Colorectal Cancer Treatments and Studies (7 papers), Blood groups and transfusion (7 papers), Cancer Genomics and Diagnostics (6 papers), Cancer Research and Treatments (6 papers), Cancer Treatment and Pharmacology (5 papers) and Renal Transplantation Outcomes and Treatments (4 papers). The work is most often cited by research in Internal Medicine (193 citations), Oncology (1.2k citations), Cancer Research (473 citations), Immunology (595 citations) and Hematology (230 citations). David Propper has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Frances R. Balkwill, Adrian L. Harris, Jeremy Braybrooke, Trivadi S. Ganesan, Denis Talbot, Roger Feakins, Kenneth J. O’Byrne, Jonathan Shamash, Eric Gardiner and F. Lofts. Their work appears in journals such as British Journal of Cancer, Journal of Clinical Oncology, Annals of Oncology, Cancer Research and Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact